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Tuesday, February 23, 2010 543athe hands and feet, is the most predominant. In one subtype of DA, Freeman
Sheldon Syndrome (FSS), 97% of the cases are caused by mutations in the em-
bryonic myosin heavy chain gene,MYH3. To assess the effects of this mutation
on adult muscle contractility, skeletal muscle was obtained from a needle bi-
opsy of the gastrocnemius muscle in an FSS individual (MYH3 R672C) and
a control subject were performed and skinned single muscle fibers were
dissected for measurements of contractile performance as the [Ca2þ] of phys-
iological solutions was varied. The magnitude of passive stiffness was 2x
greater for patient fibers. There was no difference in maximal Ca2þ activated
force found in the affected adult muscle fibers (0.204uN 5 0.044) compared
to normal adult muscle fibers (0.259uN 5 0.028). However specific force
was 69% less ; this was attributable to hypertrophy of the patient fibers
(159um 5 8 as compared to normal control myofibers of 87um 5 3). Little
to no change was observed in Ca2þ sensitivity (pCa50) or in cooperativity of
the force-pCa relationship. Relaxation was dramatically slower in patient
fibers, taking 4x longer to reach 50% relaxation and 10x longer to reach 90%
relaxation. Control experiments suggested this is not due to the larger patient
fiber size. Preliminary analysis, using a 12.5% agarose gel, and Western Blots,
indicated that these differences were not fiber type dependent. Interestingly,
we have identified that embryonic myosin (MYH3) is present in single adult
muscle cells. This work was supported by HL65497 (Regnier) and HD48895
(Bamshad).
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CK-1909178 is a member of a class of fast skeletal troponin activators that sen-
sitize skinned skeletal muscle fibers to calcium. In rat muscle preparations in
vitro and in situ, CK-1909178 increased sub-tetanic force without altering max-
imum force. Given that a major cause of muscle fatigue during repeated muscle
contraction is reduced myoplasmic Ca2þ due to impaired sarcoplasmic reticu-
lum Ca2þ release, we tested whether increased calcium sensitivity with CK-
1909178 would slow the development of fatigue. Rat flexor digitorum brevis
muscle was pretreated in vitro with CK-1909178 and stimulated every 3 sec-
onds at a frequency sufficient to achieve 50% of maximum force for 6 min
at 30C. CK-1909178 diminished the extent of fatigue as compared to control
(terminal force 29.558% vs. 12.754%, p<0.001). We next tested whether
CK-1909178 treatment would slow the development of muscle fatigue using
rat extensor digitorum longus muscle in situ, where the muscle was stimulated
via the peroneal nerve. To accelerate the development of muscle fatigue, vas-
cular insufficiency was produced by femoral artery ligation (FAL). Muscle fa-
tigue with FAL and sham ligation in the presence and absence of CK-1909178
was assessed. CK-1909178 was administered as a 5mg/kg intravenous bolus
before assessment of fatigue at a frequency adjusted to achieve the same force
at 30Hz prior to dosing. FAL resulted in significantly reduced terminal tension
as compared to sham (3354% vs. 7755%, p<0.01). CK-1909178 administra-
tion significantly attenuated FAL-induced fatigue at 10 minutes (6157% vs.
3354%, p<0.01). In summary, CK-1909178 increased sub-maximal muscle
force development and reduced the extent of fatigue in the presence of limited
blood flow in situ. We believe that this mechanismmay improve muscle fatigue
in diseases where blood flow to muscles is compromised such as intermittent
claudication.
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The subfragment 2/light meromyosin "hinge" region of myosin II rods forms
a less stable coiled-coil than do flanking regions. Different hinge sequences
may contribute tomuscle specific properties. Transgenic replacement of a portion
of fast muscle myosin hinge A (encoded by exon 15a) in Drosophila indirect
flight muscle (IFM) with slow muscle hinge B (exon 15b) increases rod
coiled-coil propensity, rod and sarcomere lengths and decreases flight perfor-
mance. To characterize the hinges’ nano-mechanical properties we determined
persistence length (PL) differences via electron microscopy and molecular
dynamic (MD) simulations. Rotary shadowed 15b myosin molecules showed
an ~22% higher rod PL relative to 15a (64.2 vs. 50.3 nm) while MD simulationsrevealed an ~39% greater PL for 15b relative to 15a (85 vs. 52 nm). These data
are consistent with a high coiled-coil propensity of exon 15b-containing myosin
rods stiffening the hinge and a substantial portion of the myosin tail. We inves-
tigated myofibrillar ultrastructure by electron microscopy of ultrathin sections of
15b-expressing IFM and observed some sarcomeres with substantially different
Z- to M-line distances on opposing halves of individual sarcomeres. We used
confocal microscopy to quantitatively assess the extent of this asymmetry as
well as the distribution of sarcomeres lengths (SL).We confirmed an ~8% greater
SL, as well as a significant difference between the coefficients of variation in SL,
in hinge B- relative to hinge A-containing myofibrils (3.5550.28 vs. 3.2950.14
mm) (F¼3.39 (p<0.001)).Our data suggest 15b hinge replacement has a stiffen-
ing effect on IFM myosin rods. This may decrease local rod flexibility, promote
molecular packing during filamentous growth and disrupt the regulation of thick
filament lengths, which in turn may account for longer and highly variable SL
and for decreased muscle performance.
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Dystroglycan and the sarcoglycan complex are two essential components of the
dystrophin-glycoprotein complex. Mutations that lead to hypoglycosylation of
dystroglycan result in various limb-girdle and congenital muscular dystrophies
referred to as dystroglycanopathies. Mutations in the genes that encode for sar-
coglycans are associated with limb-girdle muscular dystrophies referred to as
sarcoglycanopathies. Overexpression of the glycosyltransferase LARGE1 in-
duces hyperglycosylation of dystroglycan and bypasses glycosylation defects
present in several distinct dystroglycanopathies. Whether LARGE1 ovexpres-
sion improves contractile properties in dystroglycanopathies and whether the
efficacy of LARGE1 overexpression extends to sarcoglycanopathy has not
been evaluated. We tested the hypothesis that muscle specific LARGE1 over-
expression reduces pathology, increases force production, and protects muscles
of mice deficient in LARGE1 (LARGEmyd mice) or b-sarcoglycan (Sgcb-null
mice) from contraction-induced injury. Mice with LARGE1 overexpression
driven by the muscle creatine kinase promoter were crossed with LARGEmyd
and Sgcb-null mice. Extensor digitorum longus muscles were isolated, specific
forces measured, and force deficits after lengthening contractions were as-
sessed. Functional expression of LARGE1 overexpression and dystroglycan
hyperglycosylation were observed. LARGE1 overexpression in LARGEmyd
mice reduced pathology and improved specific force and force deficit to
wild-type levels. In contrast, overexpression had no beneficial effect for
Sgcb-null mice. The results suggest that the efficacy of muscle specific
LARGE1 overexpression may be limited to dystroglycanopathies.
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Post-translational modifications of the proteins that make up the cardiac sarco-
mere have been suggested as a source of pathological muscle dysfunction. Re-
active oxygen species (ROS) can induce post-translational modifications to
proteins, and an increase in ROS levels is recognized as a feature of heart fail-
ure following myocardial infarction (MI). The experiments described here test
the hypothesis that MI exerts a functional effect through alteration of myofibril-
lar proteins, which can be detected within days after the infarction. Experimen-
tal MI was induced by ligation of the left anterior descending coronary artery in
6-month old female CD1 mice. Samples were collected 3-4 days after ligation
or sham surgery (n¼ 10). We performed functional analysis through force-cal-
cium measurements of detergent-extracted fiber bundles ("skinned fibers") dis-
sected from non-infarcted papillary muscle. Our findings included an increase
in Caþþ sensitivity in fibers from MI hearts compared to those from sham-op-
erated animals and a decreased cooperativity of activation (p < 0.05). Bio-
chemical data derived from electrophoresis of isolated myofibrillar proteins
from these hearts revealed both oxidation and modified phosphorylation. We
used ProQ Diamond phosphoprotein gel stain to analyze myofilament protein
phosphorylation, and nonreducing-reducing "diagonal" SDS-PAGE to detect
the formation of disulfide products. Total troponin I phosphorylation levels
